Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities

Single institution case series review with a histological diagnosis of mixofibrosarcoma of the extremities from 01 Jan 1993 to 01 Dec 2017.

The study will exam all the clinical, radiological, histological and immunohistochemical features of this tumour in all samples and in a limited serie of cases the presence of mutation of 50 genes cancer related.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcoma,Soft Tissue Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Sarcoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istituto Ortopedico Rizzoli

Bologna, BO, 40136, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and female patients treated at Rizzoli Institute from 01 Jan 1993 to 01 Dec 2017
Diagnosis of mixofibrosarcoma of extremities
Histological slides/formalin-fixed paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the histology analysis and molecular analysis
Enough tumor biobanked material available for molecular analysis
Presence of the biobank signed informed consent
Written informed consent prior to any study-specific analysis and/or data collection

Exclusion criteria

Patients with histological diagnosis different from mixofibrosarcoma of extremities

Treatment and study plan

case series review of clinical and histological data

Other

We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.

Primary outcomes

disease-free survival

Time frame: at baseline (Day0)

identify patients with different risk classes in terms of disease-free survival (local and systemic recurrence).
overall survival

Time frame: at baseline (Day0)

identify patients with different risk classes in terms of overall survival.

Sponsors and collaborators

Lead sponsor

Istituto Ortopedico Rizzoli

Other

Registry information

Official study title

Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities: Diagnostic and Prognostic Impact

Acronym: MFS

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Aug 5, 2021
Registry last updated: May 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed